Wockhardt Ltd (Wockhardt) manufactures and commercializes pharmaceutical formulations, active pharmaceutical ingredients (APIs), biosimilars, and vaccines. The company focuses on addressing antimicrobial resistance (AMR) through its innovative portfolio of novel antibiotics. The company’s development capabilities are focused on new chemical entities (NCE), abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS), analytical technologies and formulation development. Wockhardt’s pipeline comprises anti-infectives in various stages of clinical development.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Wockhardt focuses on the development of new chemical entities (NCEs), generics, abbreviated new drug applications (ANDAs), biosimilars, and novel drug delivery systems (NDDS). The company’s R&D activities focus on developing antibacterial solutions to combat antimicrobial resistance (AMR). The company has established a multi-disciplinary team of over 125 scientists at the Wockhardt Research Center in Chhatrapati Sambhajinagar, India. This team works across various fields, including medicinal chemistry, microbiology, molecular biology, and pharmacokinetics, to develop novel antibiotics targeting multi-drug-resistant pathogens. Wockhardt has successfully launched two novel antibiotics and has four others in various stages of clinical development. As of March 2025, the company had filed six US INDs and received over 400 patents, with 69 granted in the US. Wockhardt has also published more than 100 research papers in top-rated journals. The company has developed a strong pipeline of candidate drugs, all of which have been granted Qualified Infectious Disease Product (QIDP) status by the US FDA. As of March 2025, the company filed 3,273 patents and held 848 patents worldwide. The primary R&D unit of Wockhardt is the Wockhardt Research Center located in Chhatrapati Sambhajinagar, India. This unit is responsible for managing the company's R&D activities, including discovery research, pre-clinical and clinical development, and the formulation and manufacturing of GMP-compliant clinical batches. The unit also supports the company's end-to-end capabilities in antibiotic discovery, development, and commercialization. The company has formed major technology alliances, including partnerships with Jemincare for nafithromycin in China and GPhC for EMROK in Russia. Additionally, the National Institute of Allergy and Infectious Diseases (NIAID) has collaborated with Wockhardt Ltd for clinical trials in the US. In FY2025, the company spent INR3,390 million on its R&D activities, which as a percentage of revenue stood at 11.2% and grew 20.6% YoY.